

# FRA<sup>®</sup>MELCO

---

## The effect of FRA C12 dry on the Lasota virus (*in vitro*)

---

***TRIAL REPORT***

Public version

Trial code: SM\_DS120006

**FRAmelco**

**Sales & Marketing department**

Ruisvoorn 5, NL-4941 SB,  
Raamsdonksveer, The Netherlands

## 1. Introduction

FRA C12 dry is one of the animal feed additive products developed and produced by FRAmelco. The formulation of this specific product is based 1-monolaurin. The product is part of the Health program. Applying this product in animal feed will mainly prevent viral infections.

This report presents the results of an *in vitro* trial on the effect of different concentrations FRA C12 dry against the Lasota virus.

## 2. Material and Methods

The effect of FRA C12 dry on Lasota virus has been tested at time 0 and 15 minutes, at different concentrations of FRA C12 dry (0.01%, 0.1%, 1%, and 10%, respectively). The embryo infection dose was 50%.

## 3. Results

The effects are presented in Table 1.

**Table 1.** Effect of different concentration FRA C12 dry on the Lasota virus, at EID<sub>50</sub>

FRA C12 dry (%)	ND titer	
	Time (min) = 0	Time (min) = 15
0.01	5x10 <sup>6.65</sup>	5x10 <sup>6.38</sup>
0.1	5x10 <sup>6.16</sup>	5x10 <sup>5.61</sup>
1	5x10 <sup>6.16</sup>	5x10 <sup>5.20</sup>
10	5x10 <sup>5.21</sup>	5x10 <sup>4.43</sup>

## 4. Conclusion

The results shows that FRA C12 dry has an inhibiting effect on Lasota virus *in vitro*. This indicates that also *in vivo* FRA C12 dry might have a reducing effect on the incidence and or severity of the Lasota virus, causing New Castle Disease.

-----

For additional info about this trial please contact [R&D@framelco.com](mailto:R&D@framelco.com)